Abstract:Polyglutamine (PolyQ) diseases include a group of inherited neurodegenerative disorders caused by unstable expansions of CAG trinucleotide repeats in the coding region of specific genes. Such genetic alterations produce abnormal proteins containing an unusually long PolyQ tract that renders them more prone to aggregate and cause toxicity. Although research in the field in the last years has contributed significantly to the knowledge of the biological mechanisms implicated in these diseases, effective treatments are still lacking. In this review, we revisit work performed in models of PolyQ diseases, namely the yeast Saccharomyces cerevisiae, the nematode worm Caenorhabditis elegans and the fruit fly Drosophila melanogaster, and provide a critical overview of the high-throughput unbiased genetic screens that have been performed using these systems to identify novel genetic modifiers of PolyQ diseases. These approaches have revealed a wide variety of cellular processes that modulate the toxicity and aggregation of mutant PolyQ proteins, reflecting the complexity of these disorders and demonstrating how challenging the development of therapeutic strategies can be. In addition to the unbiased large-scale genetic screenings in non-vertebrate models, complementary studies in mammalian systems, closer to humans, have contributed with novel genetic modifiers of PolyQ diseases, revealing neuronal function and inflammation as key disease modulators. A pathway enrichment analysis, using the human orthologues of genetic modifiers of PolyQ diseases clustered modifier genes into major themes translatable to the human disease context, such as protein folding and transport as well as transcription regulation. Innovative genetic strategies of genetic manipulation, together with significant advances in genomics and bioinformatics, are taking modifier genetic studies to more realistic disease contexts. The characterization of PolyQ disease modifier pathways is of extreme relevance to reveal novel therapeutic possibilities to delay disease onset and progression in patients.

[The Advances in Research on Phosphorylation of Polyglutamine Disease].

Research advances on polyglycine diseases

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration

Conformation Polymorphism of Polyglutamine Proteins

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

A Synergistic Perspective on Theoretical and Experimental Approaches

[Poly Adenosine Diphosphate-Ribosylation and Neurodegenerative Diseases].

[Neurofilament light chain and Polyglutamine disease]

Polyglutamine spinocerebellar ataxias — from genes to potential treatments

The Polyg Diseases: a New Disease Entity

Polyglutamine spinocerebellar ataxias: emerging therapeutic targets

Gene Deregulation and Underlying Mechanisms in Spinocerebellar Ataxias With Polyglutamine Expansion

Polyglutamine Expansion in Huntingtin and Mechanism of DNA Damage Repair Defects in Huntington's Disease

Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets

Altered Metabolic Signaling and Potential Therapies in Polyglutamine Diseases

Extracellular Vesicles Physiological Role and the Particular Case of Disease-Spreading Mechanisms in Polyglutamine Diseases

DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases

Structure prediction of polyglutamine disease proteins: comparison of methods

Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity

New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors

Polyglutamine Expansion Alters the Dynamics and Molecular Architecture of Aggregates in Dentatorubropallidoluysian Atrophy